Advertisement

Loading...

Jiangsu Recbio Technology Co., Ltd.

2179.HKHKSE
Healthcare
Biotechnology
HK$4.10
HK$0.02(0.49%)
Hong Kong Market is Open • 11:46

Jiangsu Recbio Technology Co., Ltd. (2179.HK) Stock Competitors & Peer Comparison

See (2179.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2179.HKHK$4.10+0.49%2B-3.15-HK$1.30N/A
6160.HKHK$186.40+8.62%277.9B124.16HK$1.49N/A
1801.HKHK$90.50+6.60%156.4B171.51HK$0.53N/A
2269.HKHK$34.98+5.94%144.1B26.61HK$1.31N/A
9926.HKHK$139.90+7.45%128.1B-127.71-HK$1.09N/A
1177.HKHK$6.31+7.13%113.8B42.40HK$0.15+1.42%
9995.HKHK$109.10+13.88%60.7B75.10HK$1.47N/A
1530.HKHK$25.32+11.84%59.7B23.23HK$1.09+0.99%
3759.HKHK$20.88+10.95%57B21.53HK$0.97+1.05%
2696.HKHK$75.80+8.67%41.3B44.39HK$1.71N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2179.HK vs 6160.HK Comparison April 2026

2179.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2179.HK stands at 2B. In comparison, 6160.HK has a market cap of 277.9B. Regarding current trading prices, 2179.HK is priced at HK$4.10, while 6160.HK trades at HK$186.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2179.HK currently has a P/E ratio of -3.15, whereas 6160.HK's P/E ratio is 124.16. In terms of profitability, 2179.HK's ROE is -1.37%, compared to 6160.HK's ROE of +0.07%. Regarding short-term risk, 2179.HK is less volatile compared to 6160.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2179.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions